Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics - Organic & Biomolecular Chemistry (RSC Publishing)
![Cytarabine Cytosine Arabinoside Arac Molecule It Is Chemotherapy Medication Skeletal Chemical Formula Paper Packaging For Drugs Stock Illustration - Download Image Now - iStock Cytarabine Cytosine Arabinoside Arac Molecule It Is Chemotherapy Medication Skeletal Chemical Formula Paper Packaging For Drugs Stock Illustration - Download Image Now - iStock](https://media.istockphoto.com/id/1481921853/vector/cytarabine-cytosine-arabinoside-ara-c-molecule-it-is-chemotherapy-medication-skeletal.jpg?s=1024x1024&w=is&k=20&c=BKdW3vffhA8v7nMEeuwzrq7Xwbxi0SMEG6g63QQQrmI=)
Cytarabine Cytosine Arabinoside Arac Molecule It Is Chemotherapy Medication Skeletal Chemical Formula Paper Packaging For Drugs Stock Illustration - Download Image Now - iStock
![Selleck Chemical LLC Cytarabine 50mg 147-94-4 Cytarabin, Ara-C, Arabinofuranosyl | Fisher Scientific Selleck Chemical LLC Cytarabine 50mg 147-94-4 Cytarabin, Ara-C, Arabinofuranosyl | Fisher Scientific](https://assets.fishersci.com/TFS-Assets/CCG/product-images/VN00119422-S1648-CYTARABINE.JPG-650.jpg)
Selleck Chemical LLC Cytarabine 50mg 147-94-4 Cytarabin, Ara-C, Arabinofuranosyl | Fisher Scientific
![Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/3865e364-f642-4c4c-b7f0-832d633f64f5/joim13553-gra-0001-m.jpg)
Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library
![Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), etc Stock Photo - Alamy Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), etc Stock Photo - Alamy](https://c8.alamy.com/comp/DXB96C/cytarabine-cytosine-arabinoside-ara-c-chemotherapy-drug-molecule-used-DXB96C.jpg)
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), etc Stock Photo - Alamy
![SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival | Leukemia SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2009.113/MediaObjects/41375_2009_Article_BFleu2009113_Fig1_HTML.jpg)
SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival | Leukemia
![Cytarabine, cytosine arabinoside, ara-C molecule. It is chemotherapy medication. Structural chemical formula and molecule model. Sheet of paper in a c Stock Vector Image & Art - Alamy Cytarabine, cytosine arabinoside, ara-C molecule. It is chemotherapy medication. Structural chemical formula and molecule model. Sheet of paper in a c Stock Vector Image & Art - Alamy](https://c8.alamy.com/comp/2RTW9J2/cytarabine-cytosine-arabinoside-ara-c-molecule-it-is-chemotherapy-medication-structural-chemical-formula-and-molecule-model-sheet-of-paper-in-a-c-2RTW9J2.jpg)
Cytarabine, cytosine arabinoside, ara-C molecule. It is chemotherapy medication. Structural chemical formula and molecule model. Sheet of paper in a c Stock Vector Image & Art - Alamy
![IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review](https://pub.mdpi-res.com/ijms/ijms-22-04955/article_deploy/html/images/ijms-22-04955-g002.png?1620369188)
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
![Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and lymphoma. Skeletal formula. Stock Illustration | Adobe Stock Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and lymphoma. Skeletal formula. Stock Illustration | Adobe Stock](https://as2.ftcdn.net/v2/jpg/01/87/81/49/1000_F_187814900_030z9cw3hZWMsn5bva1i7hIJ4m7PrtBh.jpg)
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and lymphoma. Skeletal formula. Stock Illustration | Adobe Stock
![RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. | Semantic Scholar RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a2e4924362c1813bb892059e09186c4a455f33ad/2-Figure1-1.png)
RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. | Semantic Scholar
![Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells](https://www.mdpi.com/molecules/molecules-22-00499/article_deploy/html/images/molecules-22-00499-g001.png)
Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells
![Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers](https://pub.mdpi-res.com/cancers/cancers-13-00966/article_deploy/html/images/cancers-13-00966-g001-550.jpg?1614819317)
Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
![Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-52703-7/MediaObjects/41598_2019_52703_Fig1_HTML.png)
Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports
![Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies | Leukemia Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2012.1/MediaObjects/41375_2012_Article_BFleu20121_Fig1_HTML.jpg)